Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh

KKRX:950210
3,750.00
KRW
+5.00
(+0.13%)
-2,030.29EPS
388.22BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh carries a market capitalization of 388.22B, placing it among publicly traded companies globally. Its enterprise value stands at 500.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap388.22B
Enterprise Value500.21B

Share Statistics

As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60.10M shares outstanding.

Shares Outstanding60.10M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 14.98, and the price-to-book ratio stands at 0.90.

PS Ratio14.98
PB Ratio0.90
P/TBV Ratio1.67
P/FCF Ratio-5.77
P/OCF Ratio-6.95

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 19.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 500.21B versus a market cap of 388.22B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales19.31

Financial Position

As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

Current Ratio0.75
Quick Ratio0.46
Debt / Equity20.93
Debt / EBITDA-1.14

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh posted a negative return on equity (ROE) of -21.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.26, reflecting losses generated across the asset base. The company generates approximately 391.08M in revenue per employee across its workforce of 66.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.41 indicates how many times Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-21.57
Return on Assets (ROA)-12.26
Revenue Per Employee391.08M
Employee Count66.25
Inventory Turnover1.41

Taxes

KRW

Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh recorded an income tax benefit of -149.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -122.14B and -90.92B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-149.09M

Stock Price Statistics

KRW

As of the close on November 17, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh's stock has declined approximately 69.11% over the past 52 weeks. The 50-day moving average sits at 5,284.30, while the 200-day moving average is 7,488.23.

52-Week Price Change-69.11%
50-Day Moving Average5,284.30
200-Day Moving Average7,488.23

Income Statement

KRW

Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh generated 25.91B in revenue and converted that into -90.92B in net income, yielding earnings per share of -2,030.29. EBITDA reached -92.58B, while operating income came in at -92.58B.

Revenue25.91B
Gross Profit-16.34B
Operating Income-92.58B
Pretax Income-122.14B
Net Income-90.92B
EBITDA-92.58B
EBIT-92.58B
Earnings Per Share (EPS)-2,030.29

Balance Sheet

KRW

As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh holds 65.95B in cash and equivalents against 105.58B in total debt, resulting in a net debt position of 38.60B. Total book value stands at 432.03B, with working capital of -36.19B providing operational flexibility.

Cash & Cash Equivalents65.95B
Total Debt105.58B
Net Debt38.60B
Equity (Book Value)432.03B
Book Value Per Share7,188.96
Working Capital-36.19B

Cash Flow

KRW

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh produced -55.82B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.50B in capital expenditures, free cash flow totaled -67.31B - equivalent to -1,120.34 per share.

Operating Cash Flow-55.82B
Capital Expenditures-11.50B
Free Cash Flow-67.31B
FCF Per Share-1,120.34

Margins

Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh posted a gross margin of -63.05, reflecting its pricing power and cost economics. The operating margin of -357.34 and net profit margin of -350.90 provide insight into operational efficiency.

Gross Margin-63.05
Operating Margin-357.34
Pretax Margin-471.41
Profit Margin-350.90
EBITDA Margin-357.34

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 13.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh shareholders.

Shareholder Yield13.09
FCF Yield-17.34

Scores

As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has an Altman Z-Score of -0.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.64